Loading clinical trials...
Loading clinical trials...
Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis: a Multicenter Randomized, Placebo Controlled, Double-blind Clinical Study
Conditions
Interventions
Norflo Oro
Placebo for Norflo Oro
Locations
1
United States
Bascom Palmer Eye Institute
Miami, Florida, United States
Start Date
December 19, 2018
Primary Completion Date
August 20, 2020
Completion Date
December 30, 2020
Last Updated
March 28, 2022
NCT07218770
NCT05486468
NCT02706704
NCT06431373
NCT07262437
NCT07176130
Lead Sponsor
Eye Pharma
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions